BMRN vs MBRX · P/E 40, rev $1.76B vs $8.2M cap
Biomarin Pharmaceutical Inc (BMRN) versus Moleculin Biotech Inc (MBRX) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. MBRX currently screens at market cap $8.2M.
Not investment advice. Open the BMRN and MBRX stock pages for the full models.
Not investment advice.